Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
705 (USA) · Dr. Muller
consented 2013-11-27
AEs
1
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Mild RASH — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-12-25 (study day 29.0); relationship: POSSIBLE
Data queries
No data queries.